Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, Multicenter, Randomized, Double-blind, Placebo controlled, Dose-escalation
study to evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of
SAP-001 in Gout Patients with Hyperuricemia. The study will be single dose ascending cohorts
across three doses with a placebo control arm.